



## Entasis Therapeutics Awarded Contract from National Institutes of Health

July 6, 2020

WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced it has entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The initial award of approximately \$3 million, with the potential to increase up to \$15.5 million, will be used to develop novel molecules from its non- $\beta$ -lactam inhibitor (NBP) platform with expanded antimicrobial spectrum.

"We are extremely pleased that NIAID has awarded Entasis this contract that will help further expand the scope of our NBP program," commented Dr. Ruben Tommasi, Chief Scientific Officer of Entasis Therapeutics. "This funding validates the pre-clinical safety and efficacy data demonstrated by our lead NBP candidate, ETX0462, in both in vivo and in vitro models against drug-resistant *Pseudomonas aeruginosa* infections, and the potential of the NBP platform to deliver additional molecules with expanded antimicrobial spectrum. We look forward to pursuing development of additional candidates from this novel class of Gram-negative antibiotics."

Funding from the contract will support research towards developing molecules with expanded Gram-negative spectrum against antibiotic resistant bacterial pathogens including *E. coli*, *Acinetobacter*, *Pseudomonas* and *Klebsiella*. Subject to achieving pre-defined milestones, the contract will fund work up to IND-ready stage. National Institutes of Health, National Institute of Allergy and Infectious Diseases contract 75N93020C00017.

### About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting *Pseudomonas* infections). For more information, visit [www.entasistx.com](http://www.entasistx.com).

### Entasis Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis' collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis' control. These and other risks and uncertainties are described more fully in the Entasis' filings with the U.S. Securities and Exchange Commission, including the section titled "Risk Factors" contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

### Entasis Company Contact

Kyle Dow  
Entasis Therapeutics  
(781) 810-0114  
[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Investor Relations Contacts

Tram Bui / James Salierno  
The Ruth Group  
(646) 536-7035 / 7028  
[tbui@theruthgroup.com](mailto:tbui@theruthgroup.com)  
[jsalierno@theruthgroup.com](mailto:jsalierno@theruthgroup.com)

### Media Contact

Kirsten Thomas  
The Ruth Group  
(508) 280-6592  
[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)



Source: Entasis Therapeutics Holdings Inc.